These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 28513427)
1. Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus . Zang YN; Zhang MJ; Wang YT; Wang C; Wang Q; Zheng QS; Ji LN; Guo W; Fang Y Int J Clin Pharmacol Ther; 2017 Aug; 55(8):650-658. PubMed ID: 28513427 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. Wang Y; Xu B; Zhu L; Lou K; Chen Y; Zhao X; Wang Q; Xu L; Guo X; Ji L; Cui Y; Fang Y Clin Drug Investig; 2017 Dec; 37(12):1107-1115. PubMed ID: 28932995 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. Watson E; Jonker DM; Jacobsen LV; Ingwersen SH J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507 [TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus. Wang K; Feng L; Zhang J; Zou Q; Xu F; Sun Z; Tang F; Chen L Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973 [TBL] [Abstract][Full Text] [Related]
7. Exenatide pharmacokinetics in healthy Chinese subjects. Zhao X; Cui YM; Zhou Y; Zhang HL; Yeo KP; Linnebjerg H; Tham LS; Kothare P; Teng LL; Mace K; Soon D Int J Clin Pharmacol Ther; 2008 Sep; 46(9):459-65. PubMed ID: 18793576 [TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. Cirincione B; Edwards J; Mager DE AAPS J; 2017 Mar; 19(2):487-496. PubMed ID: 27896683 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. Kothare PA; Linnebjerg H; Isaka Y; Uenaka K; Yamamura A; Yeo KP; de la Peña A; Teng CH; Mace K; Fineman M; Shigeta H; Sakata Y; Irie S J Clin Pharmacol; 2008 Dec; 48(12):1389-99. PubMed ID: 19047364 [TBL] [Abstract][Full Text] [Related]
10. [Not Available]. Salvador J; Gaztambide S Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835 [No Abstract] [Full Text] [Related]
11. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Gao W; Jusko WJ Drug Metab Dispos; 2012 May; 40(5):990-7. PubMed ID: 22338110 [TBL] [Abstract][Full Text] [Related]
12. Is exenatide advancing the treatment of type 2 diabetes? Doggrell SA Expert Opin Pharmacother; 2006 Jan; 7(1):109-12. PubMed ID: 16370928 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus. Cui YM; Guo XH; Zhang DM; Tham LS; Tang CC; Mace K; Linnebjerg H J Diabetes; 2013 Jun; 5(2):127-35. PubMed ID: 23332026 [TBL] [Abstract][Full Text] [Related]
14. Exenatide. Bray GM Am J Health Syst Pharm; 2006 Mar; 63(5):411-8. PubMed ID: 16484515 [TBL] [Abstract][Full Text] [Related]
15. Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly. Shaw JE; Gallwitz B; Han J; Hardy E; Schernthaner G Diabetes Obes Metab; 2017 Dec; 19(12):1793-1797. PubMed ID: 28573708 [TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis. Yu H; Åstrand M; Cheng J; Nitin K; Hamrén B; Khan AA Clin Pharmacokinet; 2024 Feb; 63(2):255-267. PubMed ID: 38236561 [TBL] [Abstract][Full Text] [Related]
17. The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. Zhu L; Wang H; Sun X; Rao W; Qu W; Zhang Y; Sun L J Pharm (Cairo); 2014; 2014():713650. PubMed ID: 26556199 [TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412 [TBL] [Abstract][Full Text] [Related]
20. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L; Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]